At the news
? BULLISHIMPACT 7/10 8-K filed Aug 5, 2026 at 07:02 ET
Q32 Bio reported positive bempikibart 36-week topline results from the SIGNAL-AA Phase 2a trial in severe/very severe alopecia areata, demonstrating a 35.3% mean SALT reduction and 40% SALT-20 response rate (mITT) with a favorable safety profile. The company completed a $200M public offering in July 2026, extending cash runway through Phase 3 topline results from a planned registration-directed program expected to initiate in H1 2027. This filing confirms a major clinical catalyst and strong capitalization for a pivotal program.
- Bempikibart achieved 35.3% mean SALT reduction from baseline at Week 36 (mITT) and 40% SALT-20 response rate; well-tolerated with no new safety signals.
- Registration-directed program in severe/very severe AA expected to initiate in H1 2027 subject to regulatory discussions in H2 2026.
- Completed $200M public offering in July 2026, raising gross proceeds before expenses.
- Cash and cash equivalents were $106.3M as of June 30, 2026, plus offering proceeds expected to fund through Phase 3 topline results.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access